Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 4Completed 2Available 2Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Neuroendocrine Tumors 19Carcinoid Tumor 7Pheochromocytoma 6Thyroid Carcinoma, Anaplastic 5Pituitary Neoplasms 5Paraganglioma 5Insulinoma 5Somatostatinoma 4Vipoma 3Serotonin Syndrome 3Lung Neoplasms 3Glucagonoma 3Gastro-enteropancreatic neuroendocrine tumor 3Gastrinoma 3Carcinoma, Neuroendocrine 3Carcinoma, Merkel Cell 3Carcinoma, Medullary 3Carcinoma, Islet Cell 3Thyroid Neoplasms 2Small Cell Lung Carcinoma 2Prostatic Neoplasms 2Pancreatic Neoplasms 2Neuroblastoma 2Neoplasms, Unknown Primary 2Neoplasms 2Multiple Endocrine Neoplasia Type 1 2Head and Neck Neoplasms 2Growth Hormone-Secreting Pituitary Adenoma 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2

Interventions

pasireotide 1Solutions 1Saline Solution 1Injections 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Hyperinsulinism × Endocrine × Clear all
NCT03053284 2021-05-14

Pasireotide in Hyperinsulinemic Hypoglycemia

Montefiore Medical Center

Phase 2 Withdrawn
Endocrine

Hyperinsulinism, Insulinoma, Congenital Hyperinsulinism

Data powered by HemOnc (CC BY 4.0) Colophon âš¡